Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02220114
Other study ID # TGO-VGB-III-01
Secondary ID
Status Completed
Phase N/A
First received August 14, 2014
Last updated April 23, 2018
Start date May 2014
Est. completion date December 2016

Study information

Verified date April 2018
Source Targeon SAS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The sponsor is developing a new paediatric formulation of vigabatrin to better adjust the dose to body weight and to limit waste of unused drug. The currently marketed vigabatrin (Sabril™) form only exists as 500 mg film coated tablets (for adults and children above 6 years) and 500 mg granules for oral solution sachets (for infants and children below 6 years). Sabril™ is not adapted for administration to infants when a fraction of the sachet is needed. Manual splitting of the sachet or lengthy and error-prone dilutions are often required.

This study is a descriptive, non-randomized, open label multi-centric acceptability study in infants and children affected with infantile spasms. The primary objective is to describe the adherence to the new formulation. Secondary objectives include:

- evaluation of the palatability and user-friendliness of the new treatment,

- evaluation of the pharmacokinetic parameters of the new formulation,

- PK parameters,

- evaluation of the tolerance,

- measurement of taurine plasma levels. This study will recruit up to 40 patients with infantile spasms and pharmacoresistant partial epilepsy aged 1 month to 6 years in 23 clinical sites in France.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 1 Month to 6 Years
Eligibility Inclusion Criteria:

- Patients with diagnosed infantile spasms (IS) or pharmacoresistant partial onset seizures (POS).

- Infants > 1 month and < 6 months; infants > 6 months and < 2 years; and children > 2 years and < 6 years.

- Patients under Sabril® or naive patients.

- Patients under a twice-a-day posology of Sabril® or patients for whom vigabatrin will be given twice daily.

Non inclusion Criteria:

- Use of more than 2 other antiepileptic drugs as concomitant treatment (including steroids). Ketogenic diet can be in addition to these 2 other antiepileptic drugs.

- Subjects receiving vigabatrin through a gastric tube.

- Weight < 1.750 Kgs.

- Any planned major surgery within the duration of the trial.

- Participation in any other clinical trial within 3 months prior to V1.

Study Design


Intervention

Drug:
Vigabatrin: Vigabatrin new ST formulation then Sabril®
first "treatment" phase (V1/D1-V3/D84), in which patients already under Sabril® "granules for oral solution" and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC. second "treatment" phase (V3/D84-V4/D98) in which the patient is switched to Sabril® "granules for oral solution" (supplied by sponsor) for 15 days at the same dose as under the new ST formulation. Dose and treatment regimen should be maintained as in first treatment phase. - At V4/D98, patients who received Sabril® "granules for oral solution" (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision).

Locations

Country Name City State
France Service de neurologie pédiatrique - CHU Amiens
France Service de neurologie pédiatrique - CHU Angers
France Service de neuropédiatrie - CHU Pellegrin Enfants Bordeaux
France Service de neurologie infantile - Hôpital Salengro Lille
France Service de nuerologie pédiatrique - Hôpital Femme Mère Enfant Lyon
France Service de neurologie pédiatrique - Hôpital de la Timone Marseille
France Service de neurologie pédiatrique - Hôpital Necker Enfants Malades Paris
France Service de neuropédiatrie - Hôpital Robert Debré Paris
France Service de neurologie pédiatrique - Hôpital Sud Rennes
France Centre référent des épilepsies rares pédiatrique associé - Hôpital de Hautepierre Strasbourg
France Service de neuropédiatrie - Hôpital Purpan Toulouse
France Service de neuropédiatrie - Hôpital de Clocheville Tours

Sponsors (4)

Lead Sponsor Collaborator
Targeon SAS Hospices Civils de Lyon, Institut National de la Santé Et de la Recherche Médicale, France, National Research Agency, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Individual adherence to the new Soluble Tablets (ST) formulation of Vigabatrin (VGB) using Medication Event Monitoring System (MEMS) Adherence will be assessed by measurement of the dosing history of patients using an electronic Medication Event Monitoring System (MEMS).The date and time of each opening will be recorded from V1 (day 1) to V3 (day 84), continuous assessment.
Secondary Adherence to the new ST formulation and to Sabril® granules for oral solution, by treatment unit accountability Accountability of used and unused treatment units, retrieved by the patient at V3 and V4 VGB-ST: V1 (day 1) to V3 (day 84). Sabril®:V3 (day 85) to V4 (day 98)
Secondary palatability of the new ST formulation and of Sabril® "granules for oral solution". Palatability of the treatment will be evaluated using a two face visual hedonic scale filled in by the parents and/or by the child, if feasible, on a daily basis. Each "face" of the scale will be assigned a score (1 to 2), and the average score will be calculated for the group. Palatability will be considered good if the average score for the group is at least 1.5 (out of a maximum of 2; Motte et al. 2005). during 7 consecutive days: from D90 to D96 under Sabril® and from D29 to D35 under the new ST formulation
Secondary Ease of use of the new ST formulation and of Sabril® "granules for oral solution". Ease of use will be evaluated using diaries filled by the parents or care-givers during 7 consecutive days: . Time required for preparation of both new ST formulation and Sabril® administrations will be averaged and compared, together with the global use satisfaction. during 7 consecutive days: from D90 to D96 under Sabril® and from D29 to D35 under the new ST formulation.
Secondary Safety and tolerance VGB safety profile is well known. The new ST formulation is expected to be bioequivalent to Sabril®, and since the new formulation does not contain excipients known to have a recognized action or effect at the dose used, the safety of the new formulation should be similar to that of Sabril®. Hence no other measures specific to the new ST formulation are included in the clinical acceptability study. Results of electroretinogram: when available from D1 to D126; Blood assessment: at D1 & D84; Vital signs at D1, D28, D84, D98 & D126; Adverse events, serious adverse events: evaluated for the duration of study participation (at D1, D28, D84, D98 & D126)
Secondary pharmacokinetic parameters for the new ST formulation (1 sample). Pharmacokinetic parameters for the new ST formulation (population PK) : Area under the curve (AUC), Tmax, Cmax, T½, Ka, V/F, Cl/F The objective is to better characterize the developmental PK of vigabatrin during childhood. PK D84: 1 sample before treatment.
Secondary Evaluation of the taurine plasma levels in children treated by vigabatrin. Taurine plasma concentration will be measured and a relationship between vigabatrin exposition and taurine plasma levels will be sought. 1 sample will be drawn at V3 (day 84): just before treatment when patient is fasting.
See also
  Status Clinical Trial Phase
Withdrawn NCT02299115 - Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms Phase 3
Completed NCT02885389 - Molecular Genetics in Infantile Spasms N/A
Completed NCT01006811 - Use of the Modified Atkins Diet in Infantile Spasms Phase 2/Phase 3
Completed NCT01828437 - Addition of Pyridoxine to Prednisolone in Infantile Spasms Phase 3
Recruiting NCT01858285 - Genetics of Epilepsy and Related Disorders
Completed NCT00552045 - Epilepsy Phenome/Genome Project
Completed NCT02954887 - Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) Phase 3
Completed NCT02092883 - Evaluation of Neuroinflammation in Children With Infantile Spasms Phase 4
Completed NCT01723787 - Genetic Studies in Patients and Families With Infantile Spasms
Withdrawn NCT01413711 - An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms Phase 4
Completed NCT00441896 - A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms Phase 2
Terminated NCT00442104 - Open-label Extension to Protocol 1042-0500 Phase 2
Completed NCT01575639 - Prednisolone in Infantile Spasms- High Dose Versus Usual Dose Phase 3
Withdrawn NCT01549288 - Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy Phase 2/Phase 3
Not yet recruiting NCT06315829 - Artificial Intelligence-based Video Analysis to Detect Infantile Spasms
Completed NCT01073579 - Sabril Patient Registry N/A
Completed NCT02953548 - Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) Phase 3
Completed NCT00001325 - Metabolic Abnormalities in Children With Epilepsy N/A
Completed NCT00968136 - Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study N/A